Sionna Therapeutics, Inc. (SION)

NASDAQ: SION · Real-Time Price · USD

51.04

+1.43 (2.88%)

At close: Aug 7, 2026, 4:00 PM EDT

49.61

-1.43 (-2.80%)

After-hours: Aug 7, 2026, 7:34 PM EDT

2.88% (1D)

Market Cap	2.31B +208.2%
Revenue (ttm)	n/a
Net Income	-97.38M
EPS	-2.17
Shares Out	45.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	747,526
Open	50.86
Previous Close	49.61
Day's Range	49.30 - 54.97
52-Week Range	16.87 - 54.97
Beta	n/a
Analysts	Buy
Price Target	53.20 (+4.23%)
Earnings Date	Aug 6, 2026

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 7, 2025

Employees 59

Stock Exchange NASDAQ

Ticker Symbol SION

Website https://www.sionnatx.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for SION stock is "Buy." The 12-month stock price target is $53.2, which is an increase of 4.23% from the latest price.

Price Target

$53.2

(4.23% upside)

Analyst Consensus: Buy

Stock Forecasts

News

Sionna Therapeutics price target raised to $60 from $50 at Guggenheim

Guggenheim raised the firm’s price target on Sionna Therapeutics (SION) to $60 from $50 and keeps a Buy rating on the shares.

1 day ago - TheFly

Sionna Therapeutics Slides: Corporate presentation

Sionna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.

2 days ago - Filings

Sionna Therapeutics reports Q2 EPS (66c), consensus (64c)

“We continued to advance our clinical NBD1 stabilizer programs during the second quarter as we approach two important clinical milestones this summer,” said Mike Cloonan, President and Chief Executive...

2 days ago - TheFly

Sionna Therapeutics Reports Second Quarter 2026 Financial Results

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

2 days ago - GlobeNewsWire

Sionna Therapeutics Earnings release: Q2 2026

Sionna Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.

2 days ago - Filings

Sionna Therapeutics Quarterly report: Q2 2026

Sionna Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.

2 days ago - Filings

Sionna Therapeutics rises 9.2%

Sionna Therapeutics (SION) is up 9.2%, or $4.15 to $49.44.

22 days ago - TheFly

Sionna Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Two pivotal data readouts are expected in summer 2026: a phase II-A proof-of-concept for the 719 NBD1 stabilizer as an add-on to Trikafta, and phase I data for dual combinations. Achieving a 10 mmol/L sweat chloride reduction is the key efficacy bar, with future strategy and expansion hinging on these results.

2 months ago - Transcripts

Sionna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

A novel approach targeting the NBD1 domain in cystic fibrosis aims to address unmet needs for the majority of patients not reaching normal CFTR function. Two lead compounds, SION-719 and SION-451, are advancing in parallel with pivotal data expected in summer 2026.

2 months ago - Transcripts

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for c...

2 months ago - GlobeNewsWire

Sionna Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Two clinical-stage NBD1 stabilizers are advancing in cystic fibrosis, with key phase II and healthy volunteer data expected this summer. The company prioritizes a novel dual combination targeting broad patient needs, aiming for superior efficacy and validated by robust assay science.

2 months ago - Transcripts